Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
When and how do I use neoadjuvant chemotherapy for breast cancer?
Rapoport BL, Demetriou GS, Moodley SD, Benn CA. Rapoport BL, et al. Among authors: demetriou gs. Curr Treat Options Oncol. 2014 Mar;15(1):86-98. doi: 10.1007/s11864-013-0266-0. Curr Treat Options Oncol. 2014. PMID: 24306808 Review.
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA. Awada A, et al. JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237. JAMA Oncol. 2016. PMID: 27078022 Clinical Trial.
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.
Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J, Burgess LJ. Ruff P, et al. Among authors: demetriou gs. Cancer Chemother Pharmacol. 2009 Sep;64(4):763-8. doi: 10.1007/s00280-009-0925-9. Epub 2009 Feb 25. Cancer Chemother Pharmacol. 2009. PMID: 19241078 Clinical Trial.
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart M. Spraggs CF, et al. Pharmacogenomics J. 2018 May 22;18(3):480-486. doi: 10.1038/tpj.2017.39. Epub 2017 Aug 8. Pharmacogenomics J. 2018. PMID: 28786423 Clinical Trial.
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M; ALTTO Steering Committee and Investigators. Moreno-Aspitia A, et al. Eur J Cancer. 2021 May;148:287-296. doi: 10.1016/j.ejca.2021.01.053. Epub 2021 Mar 23. Eur J Cancer. 2021. PMID: 33765513 Free PMC article. Clinical Trial.
17 results